Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. doi:10.1016/j.cell.2011.02.013
CAS
Article
PubMed
Google Scholar
Gocheva V, Joyce JA (2007) Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6(1):60–64
CAS
Article
PubMed
Google Scholar
Yang Y, Lim S-K, Choong L-Y, Lee H, Chen Y, Chong P-K, Ashktorab H, Wang TT, Salto-Tellez M, Yeoh K-G (2010) Cathepsin S mediates gastric cancer cell migration and invasion via a putative network of metastasis-associated proteins. J Proteome Res 9(12):6801
CAS
Article
Google Scholar
Gormley J, Hegarty S, O’Grady A, Stevenson M, Burden R, Barrett H, Scott C, Johnston J, Wilson R, Kay E (2011) The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study. Br J Cancer 105(10):1487–1494
CAS
Article
PubMed
PubMed Central
Google Scholar
Sage J, Mallèvre F, Barbarin-Costes F, Samsonov SA, Gehrcke J-P, Pisabarro MT, Perrier E, Schnebert S, Roget A, Livache T (2013) Binding of chondroitin 4-sulfate to cathepsin S regulates its enzymatic activity. Biochemistry 52(37):6487–6498
CAS
Article
PubMed
Google Scholar
Shi G-P, Webb AC, Foster KE, Knoll J, Lemere CA, Munger JS, Chapman HA (1994) Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. J Biol Chem 269(15):11530–11536
CAS
PubMed
Google Scholar
Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D, Joyce JA (2006) Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20(5):543–556
CAS
Article
PubMed
PubMed Central
Google Scholar
Burden RE, Gormley JA, Jaquin TJ, Small DM, Quinn DJ, Hegarty SM, Ward C, Walker B, Johnston JA, Olwill SA (2009) Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis. Clin Cancer Res 15(19):6042–6051
CAS
Article
PubMed
Google Scholar
Ryschich E, Lizdenis P, Ittrich C, Benner A, Stahl S, Hamann A, Schmidt J, Knolle P, Arnold B, Hämmerling GJ (2006) Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res 66(1):198–211
CAS
Article
PubMed
Google Scholar
Fernández PL, Farré X, Nadal A, Fernández E, Peiró N, Sloane BF, Shi GP, Chapman HA, Campo E, Cardesa A (2001) Expression of cathepsins B and S in the progression of prostate carcinoma. Int J Cancer 95(1):51–55
Article
PubMed
Google Scholar
Fan Q, Wang X, Zhang H, Li C, Fan J, Xu J (2012) Silencing cathepsin S gene expression inhibits growth, invasion and angiogenesis of human hepatocellular carcinoma in vitro. Biochem Biophys Res Commun 425(4):703–710
CAS
Article
PubMed
Google Scholar
Wang B, Sun J, Kitamoto S, Yang M, Grubb A, Chapman HA, Kalluri R, Shi G-P (2006) Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem 281(9):6020–6029
CAS
Article
PubMed
Google Scholar
Sevenich L, Bowman RL, Mason SD, Quail DF, Rapaport F, Elie BT, Brogi E, Brastianos PK, Hahn WC, Holsinger LJ (2014) Analysis of tumour-and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat Cell Biol 16(9):876–888
CAS
Article
PubMed
PubMed Central
Google Scholar
Flannery T, McQuaid S, McGoohan C, McConnell RS, McGregor G, Mirakhur M, Hamilton P, Diamond J, Cran G, Walker B (2006) Cathepsin S expression: an independent prognostic factor in glioblastoma tumours—a pilot study. Int J Cancer 119(4):854–860
CAS
Article
PubMed
Google Scholar
Jobs E, Ingelsson E, Risérus U, Nerpin E, Jobs M, Sundström J, Basu S, Larsson A, Lind L, Ärnlöv J (2011) Association between serum cathepsin S and mortality in older adults. JAMA 306(10):1113–1121
CAS
Article
PubMed
Google Scholar
Chang W-SW, Wu H-R, Yeh C-T, Wu C-W, Chang J-Y (2007) Lysosomal cysteine proteinase cathepsin S as a potential target for anti-cancer therapy. J Cancer Mol 3(1):5–14
CAS
Google Scholar
Gautam J, Banskota S, Regmi SC, Ahn S, Jeon YH, Jeong H, Kim SJ, Nam T-G, Jeong B-S, Kim J-A Tryptophan hydroxylase 1 and 5-HT7 receptors preferentially expressed in triple-negative breast cancer promote cancer progression through autocrine serotonin signaling. Mol Cancer (under revision)
Neckers L (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8(4):S55–S61
CAS
Article
PubMed
Google Scholar
Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM (2007) High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 67(7):2932–2937
CAS
Article
PubMed
Google Scholar
Subbarao Sreedhar A, Kalmár É, Csermely P, Shen Y-F (2004) Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 562(1–3):11–15
CAS
Article
Google Scholar
Bae YK, Kim A, Kim MK, Choi JE, Kang SH, Lee SJ (2013) Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer. Hum Pathol 44(10):2028–2037
CAS
Article
PubMed
Google Scholar
Choi JE, Kang SH, Lee SJ, Bae YK (2015) Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol 22(1):82–89
Article
PubMed
Google Scholar
Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M (2007) Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res 5(2):195–201
CAS
Article
PubMed
Google Scholar
McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM (2010) Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer 10:S59–S65
Article
PubMed
Google Scholar
Jang J-Y, Jeon Y-K, Kim C-W (2010) Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells. BMC Cancer 10(1):391
Article
PubMed
PubMed Central
Google Scholar
Santagata S, Hu R, Lin NU, Mendillo ML, Collins LC, Hankinson SE, Schnitt SJ, Whitesell L, Tamimi RM, Lindquist S (2011) High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci 108(45):18378–18383
CAS
Article
PubMed
PubMed Central
Google Scholar
Geraghty P, Greene CM, O’Mahony M, O’Neill SJ, Taggart CC, McElvaney NG (2007) Secretory leucocyte protease inhibitor inhibits interferon-γ-induced cathepsin s expression. J Biol Chem 282(46):33389–33395
CAS
Article
PubMed
Google Scholar
Lee TKW, Cheung VCH, Lu P, Lau EYT, Ma S, Tang KH, Tong M, Lo J, Ng IOL (2014) Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 60(1):179–191
CAS
Article
PubMed
Google Scholar
Graham TR, Odero-Marah VA, Chung LW, Agrawal KC, Davis R, Abdel-Mageed AB (2009) PI3K/Akt-dependent transcriptional regulation and activation of BMP-2-Smad signaling by NF-κB in metastatic prostate cancer cells. Prostate 69(2):168–180
CAS
Article
PubMed
PubMed Central
Google Scholar
Aggarwal BB, Vijayalekshmi R, Sung B (2009) Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15(2):425–430
CAS
Article
PubMed
Google Scholar
Liu P, Wilson MJ (2012) miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/MEK/Erk signaling pathway and NF-κB factor in human fibrosarcoma cells. J Cell Physiol 227(2):867–876
CAS
Article
PubMed
PubMed Central
Google Scholar
Cheng XW, Shi G-P, Kuzuya M, Sasaki T, Okumura K, Murohara T (2012) Role for cysteine protease cathepsins in heart disease focus on biology and mechanisms with clinical implication. Circulation 125(12):1551–1562
Article
PubMed
Google Scholar
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et Biophysica Acta (BBA)—Mol Cell Res 1773(8):1263–1284
CAS
Article
Google Scholar
Lee S-J, Namkoong S, Kim Y-M, Kim C-K, Lee H, Ha K-S, Chung H-T, Kwon Y-G, Kim Y-M (2006) Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK-and PI3K/Akt/eNOS-dependent signal pathways. Am J Physiol Heart Circ Physiol 291(6):H2836–H2846
CAS
Article
PubMed
Google Scholar
Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, Yamanoshita O, Iida M, Ohgami N, Tamura H, Kawamoto Y (2011) RAS/RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant melanoma progression and therapy. Dermatol Res Pract 2012